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Abstract

Many chemotherapeutic drugs are small, hydrophobic molecules that require watersoluble, biocompatible nanocarriers for enhanced vascular circulation. Existing polymeric
carriers either conjugate the drug along a copolymer backbone or sequester drugs within a
protected interior domain to be delivered to specific sites in the body. Such therapeutic
systems must overcome a myriad of hurdles, beginning with complex, multi-step
syntheses, followed by other inherent barriers that limit the efficiency of drug delivery at
the targeted site. This work aims to circumvent a number of these issues using
biocompatible, stimuli-responsive polysoaps that are capable of unimeric micelle
formation, hydrophobic drug delivery, and triggered release, regardless of dilution effects.
These copolymers are prepared via RAFT copolymerization of N-(2-hydroxypropyl)
methacrylamide (HPMA) and dodecylpropyldisulfide methacrylamide (DPDMA). The
facile synthesis of these polysoaps and their ability to function at high dilution are
promising indicators of their utility in future applications.

Keywords: Drug delivery, Polysoaps, Stimuli-responsive, RAFT copolymerization
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Chapter I
Introduction and Statement of Problem

Cancer therapy state of the art
Cancer treatments today largely rely upon methods that are unable to target only
cancer cells, thus limiting the extent of treatment one can receive. Therapeutic methods
designed with the capability to discriminate solely against cancer are thus urgently desired.
As a result of severely negative side effects and the advancement of targeted drug delivery
technologies, polymeric therapeutics have rapidly become a main focus of research.1,2 High
toxicity and short half-lives of chemotherapeutic drugs have been remedied utilizing
various nanoparticle-based delivery systems that encapsulate these drugs, increasing
solubility and decreasing cytotoxicity to normal healthy tissues. 3,4 Due to drug-resistance
development capabilities of cancer cells, therapeutic oligonucleotides, such as small
interfering RNAs (siRNAs), have been explored for disrupting gene expression at the
transcriptional or translational level. These otherwise promising treatments are limited by
short half-lives in blood due to vulnerability to degradation by ribonucleases, and poor
cellular uptake5,6,7 Encapsulation of these oligonucleotides via polymeric nanoparticles has
achieved impressive results.8,9 Tailoring of these polymeric drug delivery systems offers
opportunities for passive and active targeting of cancer cells, increasing cancer cells
specificity.10 Particularly useful are folate nanoconjugates for active targeting of the folate
receptor that is overexpressed on the surface of many types of tumors, triggering receptormediated endocytosis of the polymer-drug conjugated system. Conjugation with this
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targeting moiety has led to drug delivery directly to cancerous tissues. 11 Thus, polymeric
targeted drug delivery systems have enormous potential for cancer therapy.12
Many types of small-molecule anti-cancer drugs, synthetic and natural compounds
(plant extracts), have been extensively studied as polymer conjugates. These systems rely
upon grafting of the drugs by covalent linkages that must be broken for release. Such an
approach requires drug-specific polymer design and difficult synthetic challenges.13 The
investigation proposed herein focuses on facile synthetic design that requires neither
grafting nor tailoring to a specific drug, since a wide variety of therapeutic molecules can
be delivered from a stimuli-responsive hydrophobic domain.

Polymers in drug delivery
The central goal of a drug delivery system is to release therapeutics at a desired site
within the body while maintaining an effective concentration for a desired duration.
Polymer-drug and polymer-protein conjugates, polymer micelles, and polyplexes are
among potential systems, allowing increased accumulation due to increased lifetime in the
body, protection from breakdown by enzymes, reduction in immunogenicity, enhanced
solubility, and the potential for targeting of specific anatomical sites.Error! Bookmark not defined.1
A large percentage of polymer conjugate applications are for anti-cancer therapies, for
which 70-fold increases in the concentrations of therapeutics have been realized in tumors
via the enhanced permeation and retention (EPR) effect.1 In addition, augmenting polymer
drug delivery systems with triggered release technologies makes it possible to reach cancer
cells deep within tumors.14
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Polysoaps
Polymeric amphiphiles that have the properties of surfactants and self-assemble
into ordered structures are termed polymeric micelles. Much larger in size than smallmolecule surfactants, micellar polymers have widely varying architectures. These include
block copolymers (macrosurfactants), stars, graft copolymers, dendrimers, segmented
block copolymers, and polysoaps. In seminal research, Strauss coined the term “polysoaps”
to describe statistical amphiphilic copolymers consisting of a hydrophilic backbone
accompanied by hydrophobic groups that possessed surfactant-like characteristics.15
Polysoaps are different from other surfactants in that they do not have a critical micelle
concentration, since micelles are formed through intramolecular associations. In solution,
without the concentration limitations of small molecule surfactants and block copolymers,
polysoaps self-assemble via the hydrophobic effect16 into unimeric or multimeric micelles
of widely varying structure.17 Polysoap applications center around exploiting the increased
capacity for solubilizing hydrophobic molecules, forming intramolecular micelles capable
of sequestering hydrophobes into a hydrophobic core domain even at high dilution.18
Numerous variations in structure and charge have been studied and employed for a variety
of uses, primarily for viscosity modification. Polysoap applications in drug delivery to date
have been limited to polymeric micelles formed from copolymers requiring grafting;19
however, these syntheses are multi-step, diminishing their practicality. An unexplored
route to using polysoaps for drug delivery is to produce stimuli-responsive micelles that
enable dissolution of the hydrophobic core domain and release of a payload inside the
cancer cell (Scheme 1). Such a system would provide versatility in the type of hydrophobes
sequestered and delivered.
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Scheme 1: Unimeric micelle or polysoap capable of drug sequestration and release in
water.

Stimuli-responsiveness
As has been presented previously, drug delivery via polymeric systems offers
several advantages, primarily in their capacity for controlled release of therapeutic agents.20
Through various mechanisms, stimuli-responsiveness allows for an external stimulus to
trigger various changes in the structure and properties of the delivery vehicle. These “smart
polymers” can respond to many types of chemical, physical, and mechanical stimulation,
with changes in temperature, ionic strength, and pH being the most commonly employed.21
Particularly useful in cancer therapies is the incorporation of a reduction-triggered release
of a drug upon delivery to the reductive microenvironment of cancer cells, inhibiting the
release of the sequestered drug prior to arrival at the desired site.

RAFT polymerization
Reversible addition-fragmentation chain transfer (RAFT) polymerization, shown
in Scheme 2, is a degenerative chain transfer polymerization technique that is both versatile
and precisely controllable. It is tolerant of multiple functional groups and allows for narrow
molecular weight distributions and controlled molecular weights. Polymerizations via
RAFT can be conducted in aqueous solution, allowing for both reduced toxicity and safety.
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In addition, the aqueous products are soluble and can be readily eliminated from the human
body. A statistical RAFT copolymerization technique is quite desirable since it requires
only a single synthetic step.22 The application of this facile technique to the synthesis of
polysoap drug delivery systems has potential to unlock new levels of practicality for simple
and versatile drug delivery systems.

Scheme 2. Generic RAFT polymerization scheme: I) initiation; II) initialization period;
III) addition/fragmentation and propagation.
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Chapter II
Objectives of Research

The overall goal of this research project was to develop a bio-compatible polysoap
that is capable of triggered drug release in vivo. To do this, we have designed a polysoap
scaffold that allows for the dissociation of the hydrophobic domain in the presence of the
reducing environment of the cytoplasm, allowing for triggered intracellular drug release.
This design laid the groundwork for future systems with potential to take up, transport, and
release hydrophobic cancer therapeutic drugs in the body regardless of micelle
concentration. To realize the full potential of this design, the objectives of this research
proposal were to:
1) Prepare biocompatible, responsive polysoaps via RAFT copolymerization of
HPMA and DPDMA.
2) Measure micelle properties in water using DLS, UV-Vis, and fluorescence
spectroscopy.
3) Determine model hydrophobe uptake and release efficiencies of the polysoaps
in water.
4) Determine toxicity of polysoaps.
This research can be divided into four main sections: monomer and polymer
synthesis, polysoap properties in water, hydrophobe uptake and release studies, and cell
toxicity studies. The first section involved the detailed synthesis of the monomers and
copolymers to achieve the polysoap of interest. Standard techniques such as nuclear
magnetic resonance (NMR) and Fourier transform infrared (FTIR) spectroscopy were used
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to confirm the structure of the monomers and copolymer. Molecular weight and molecular
weight distribution of the copolymers were determined using size exclusion
chromatography coupled to multiple-angle light scattering (SEC-MALS). The second
section reports DLS, UV-Vis spectroscopy, and fluorescence spectroscopy studies, used to
study micelle formation and hydrophobe uptake properties in water. The third section
details the ability of the polysoap to retain and release hydrophobic molecules in water and
in the presence of the reducing molecule, glutathione. The fourth section reports the
toxicity of the polysoaps using an MTT cell viability assay.

Scheme 3. The structure of the targeted polysoap is shown with its mechanism of uptake
and release of hydrophobic cancer drug.
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Chapter III
Materials and Methods

Materials
The monomer precursors D,L-1-amino-2-propanol (TCI, 98%), sodium
methanesulfinate (AK Scientific, 92%), sulfur (Sigma Aldrich, 100 mesh), bromo
propylamine hydrobromide (AK Scientific, 98%), and dodecanethiol (Sigma Aldrich,
98%) were used as received. Methacryloyl chloride (Aldrich, 97%) was distilled under
vacuum and stored under N2 at −10 °C prior to use. The RAFT agent precursors ethanethiol
(Sigma Aldrich, 98%), carbon disulfide (Sigma Aldrich, 99.9%), and 4,4′-azobis(4cyanopentanoic acid) (V-501) were used as received. The solvents diethyl ether (Fisher
Scientific, Spectranalyzed), pentane (Fisher Scientific, HPLC grade), acetone (Fisher
Scientific, Optima grade), anhydrous methanol (Sigma Aldrich), and 200 proof ethanol
(Decan Laboratories, anhydrous) were used as received. The initiator (96%) 2,2′-azobis(2methylpropionitrile) (AIBN) was purchased from Sigma Aldrich and recrystallized from
methanol prior to use. The internal standard, trioxane, was purchased from Sigma-Aldrich
and used as received. The detailed synthesis of the RAFT chain transfer agent 4-cyano-4(ethylsulfanylthiocarbonylsulfanyl)pentanoic

acid

(CEP)

and

monomers

N-(2-

hydroxypropyl)methacrylamide (HPMA) and (dodecylpropyldisulfide)methacrylamide
(DPDMA) are described below.
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Synthesis of 4-cyano-4-(ethylsulfanylthiocarbonyl)sulfanylpentanoic acid (CEP)
Using a procedure as previously reported,23 a suspension of sodium hydride (95%)
(2.11 g, 83.5 mmol) in anhydrous diethyl ether (150 mL) was cooled to 0 °C using an ice
bath, upon which ethanethiol (5.73 g, 92.3 mmol) was added over 15 min accompanied by
a vigorous evolution of hydrogen gas. The reaction was stirred for an additional 15 min at
0 °C followed by dropwise addition of carbon disulfide (7.03 g, 92.3 mmol) over 5 min
and the reaction stirred for 60 min at room temperature. The reaction solution was then
diluted with pentane (100 mL) and the resulting yellow precipitate isolated by vacuum
filtration before drying under vacuum to yield sodium ethyl trithiocarbonate (12.07 g, 90%)
as a hygroscopic yellow solid. To a suspension of sodium ethyl trithiocarbonate (9.89 g,
61.7 mmol) in diethyl ether (200 mL) at room temperature was added solid I2 (8.63 g, 34.0
mmol) over 5 min. The reaction was stirred for 60 min at room temperature and the
precipitated sodium iodide salts were removed by vacuum filtration and washed with 50
mL of diethyl ether. The filtrate was transferred to a separatory funnel and washed with
5% sodium dithionite (1 x 150 mL), deionized water (1 x 150 mL), and brine (1 x 150 mL)
before drying over anhydrous magnesium sulfate. The solvent was removed via rotary
evaporation followed by drying in vacuo to yield bis(ethyl) trithiocarbonate (96%) as a
yellow solid. A solution of bis(ethyl) trithiocarbonate (5.00 g, 18.2 mmol) and V-501 (7.66
g, 27.3 mmol) in ethyl acetate (250 mL) was prepared in a 500-mL 3-necked flask equipped
with stir bar and condenser. The solution was purged with N2 for 40 min prior to heating
at reflux for 18 hrs, upon which the reaction was quenched via exposure to air and cooled
to room temperature. The solvent was removed via rotary evaporation and the crude RAFT
agent purified via column chromatography on silicon dioxide (60:35:5 hexanes:ethyl
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acetate:acetic acid). To remove the acetic acid, the column fractions containing CEP were
combined and transferred to a separatory funnel and washed with 0.05 N hydrochloric acid
(2 x 150 mL) and brine (1 x 150 mL) and dried over magnesium sulfate, and the solvent
removed via rotary evaporation followed by drying under vacuum to yield CEP as a yellow
solid. Yield: 7.10 g (74%); mp: 58-60 °C; 1H NMR (300 MHz, CDCl3): δ 3.38 (q, 2H),
2.70 (t, 2H), 2.55 (m, 2H), 1.85 (s, 3H), 1.40 (t, 3H) (Figure A1).

Synthesis of N-(2-hydroxypropyl)methacrylamide (HPMA)
Using a procedure as previously reported,24 to a 2-L round bottom flask was added
D,L-1-amino-2-propanol (102.307 g) dissolved in 1 L of acetonitrile. A stir bar was added,
and the round bottom flask was sealed with a septum and placed into an ice bath. To the
reaction mixture was added methacryloyl chloride (67.80 g) dropwise over 3 hrs. The round
bottom flask was then removed from the ice bath and allowed to reach room temperature,
and then the contents were stirred for an additional 2 hrs. Solvent was removed via rotary
evaporation at 30 oC. After 2/3 of the solvent had been removed, a white crystalline salt
formed. The salt was isolated via vacuum filtration and purified by recrystallization from
minimal acetone at room temperature. The resulting product was white crystals. mp: 65-67
°C; 1H NMR (300 MHz, D2O): δ 6.60 (b, 1H), 5.70 (s, 1H), 5.30 (s, 1H), 3.90 (b, 1H), 3.70
(d, 1H), 3.10-3.60 (m, 2H), 1.9 (s, 3H), 1.2 (d, 3H) (Figure A2).

Synthesis of (dodecylproplydisulfide) methacrylamide (DPDMA)
A mixture of sodium methanesulfinate (10 g, 98 mmol) and sulfur (3.14 g, 98
mmol) in dry methanol (1.2 L) was heated to reflux using a heating manifold (set voltage
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to 50 V) and a condenser (with drying tube inserted into a rubber septum). After 18 hrs,
the sulfur had dissolved, and the reaction was stopped. The solvent was removed by rotary
evaporation, leaving behind an off-white residue. To the residue was added 500 mL of 200
proof ethanol to dissolve the desired product. After stirring for 1 hrs, not all the solids had
dissolved, and the solution was filtered via vacuum filtration. The filtrate was then
concentrated by rotary evaporation and the product was dried under high vacuum for 4 hrs,
resulting in a white powder, sodium methanethiosulfonate. To a round bottom flask
containing water (150 mL), bromo propylamine hydrobromide (5.04 g, 23.0 mmol) and
sodium methanethiosulfonate (6.01 g, 44.8 mmol) were added. The mixture was stirred at
70 °C for 18 hrs. The reaction was then removed from the heat and the solvent was removed
via rotary evaporation, leaving an off-white powder. The crude powder was then triturated
using ethanol. The solution became light yellow and the powder became white as
impurities dissolved. The product was collected via vacuum filtration and washed with
ethanol, followed by drying overnight under high vacuum. The pure product was a white
powder,

aminopropyl

sodium

methanethiosulfonate.

Aminopropyl

sodium

methanethiosulfonate (11.25 g, 54.6 mmol) was dissolved in dry methanol (200 mL), and
dodecanethiol (80 mL, 332 mmol) was added and the solution was stirred for 18 hrs at
room temperature. The contents of the reaction were then transferred to a separatory funnel.
The excess dodecane thiol was the bottom layer and methanol the top layer. The dodecane
thiol was removed from the methanol and then hexanes were added to the separatory funnel
to wash the methanol layer. The product remained in the bottom methanol layer. The
methanol layer was removed and concentrated using rotary evaporation, leaving a white
powder. The product was washed with hexanes and collected via vacuum filtration and
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dried via high vacuum. The product was further purified via column chromatography on
silica gel using chloroform with 3% triethylamine as the eluent. After the product was
isolated, it was a white powder, aminopropyl dodecyl disulfide. Aminopropyl dodecyl
disulfide (14.0 g, 43.0 mmol) was added to a round bottom flask. To the flask were then
added 300 mL of acetone and triethylamine (15.0 mL). The flask was charged with a stir
bar, sealed with a rubber septum, and placed in an ice bath. Methacroylchloride (7.0 mL,
71.6 mmol) was then added dropwise while stirring in the ice bath. The vessel was removed
from the ice bath and allowed to reach room temperature, and the reagents stirred for an
additional 18 hrs. A white precipitate had formed after adding the methacroylchloide, and
it was removed via vacuum filtration. The supernatant was then collected and removed via
rotary evaporation, leaving a brownish orange oil. The crude product was then purified via
column chromatography using chloroform as the eluent. The pure product was isolated and
dried under high vacuum, resulting in a white powder, (dodecylpropyldisulfide)
methacrylamide. Yield: 4.0 g (25%); mp: 41-43 °C; 1H NMR (300 MHz, CDCl3): δ 5.98
(s, 1H), 5.70 (s, 1H), 5.30 (s, 1H), 3.45 (q, 2H), 2.70 (q, 4H), 1.98 (b, 5H), 1.65, (m, 2H),
1.25 (b, 18H), 0.80 (t, 3H) (Figures A3-A6).

Statistical copolymerization of HPMA and DPDMA via RAFT
The general procedure is as follows: the HPMA, DPDMA, CEP, and AIBN with
desired feed ratios were added to a 25-mL polymerization flask equipped with a magnetic
stir bar. For example, HPMA (2.83 g, 19.9 mmol), DPDMA (0.377 g, 1.05 mmol), CEP
(6.50 mg, 24.7 μmol), methanol (20 mL), and AIBN (0.811 mg, 4.94 μmol) were added
with the molar ratios of HPMA:DPDMA:CEP:AIBN = 950:50:1:0.2. Trioxane (250 mg)
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was added as an internal standard. The flask was then sealed and purged with ultra-high
purity N2. After purging with N2 for 60 min, an initial aliquot of 200 μL was taken prior to
commencing the polymerization at 70 °C in an oil bath while stirring. After the desired
polymerization time of 48 hrs, an aliquot was taken and analyzed by 1H NMR (MeOH-d4)
to determine monomer conversion by comparing the relative integral areas of the signal
from the trioxane protons to those of the monomer vinyl protons. An SEC-MALS
instrument (eluent of 0.2 M LiClO4 in methanol) was used to monitor the molecular weight
and molecular weight distribution (Mw/Mn) of each polymerization. The polymer was
purified via precipitation from acetone and isolated via centrifugation. The polymer pellet
was then washed with acetone five times, followed by drying overnight under vacuum to
yield a white powder. The final product was analyzed by 1H-NMR in MeOH-d4 (Figures
A7 and A8).

Preparation of polysoap solutions
Polysoaps were solubilized in deionized water, followed by sonication, vortexing,
and shaking for 48 hrs. Solutions were prepared via serial dilutions, using an automatic
micropipette and 25-mL volumetric flasks for precision. This yielded solutions with
concentrations of 0.1, 0.5, 1.0, 3.75, and 5.0 mg/mL in deionized water.

Pyrene uptake into the core domains of the polysoaps
To study the uptake characteristics of the polysoaps, the following procedure was
used for a single trial: to a single 1.5-mL centrifuge tube was added 10 μL of 50 mg/mL
pyrene solution in acetone. The acetone was evaporated, leaving the pyrene behind. Into
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the centrifuge tube was then added the desired polysoap solution in water (1.5 mL). The
contents were vortexed and allowed to shake for 24 hrs for the solution to equilibrate. Then
the solution was centrifuged, and 1 mL of the polysoap/pyrene solution was transferred to
another centrifuge tube prior to measurement of pyrene absorbance and I3/I1 ratios via UVVis spectroscopy and fluorescence spectroscopy, respectively.

Hydrocarbon retention and release experiments
Hydrocarbon retention in water was performed using the following procedure: into
a 1.5-mL centrifuge tube was added 1 mL of 5 mg/mL polysoap solution. The solution was
prepared using 0.1 mM 9-anthracenemethanol. The contents of the centrifuge tube were
allowed to equilibrate over 24 hrs. Then the solution was transferred to a dialysis bag
(molecular weight cutoff of 1,000 g/mol). The bag with the solution was then dialyzed
against deionized water. An initial aliquot was taken for UV-Vis spectroscopy, followed
by sampling and absorbance measurements at desired times. Each aliquot was returned to
the dialysate after measurement. After several measurements, 50 mmol of glutathione was
added to the dialysate and aliquots were taken and measured via UV-Vis spectroscopy.
The following procedure was used for the hydrocarbon release experiment: to a 50mL centrifuge tube was added 5 mL of 5 mg/mL polysoap solution. The solution was
prepared using 0.1 mM 9-anthracenemethanol. The contents of the centrifuge tube were
allowed to equilibrate over 24 hrs. Ethyl acetate (5 mL) was added to the centrifuge at the
start of the experiment. An initial aliquot of the ethyl acetate was taken for UV-Vis
spectroscopy followed by sampling and measurement of the ethyl acetate layer at desired
times. Each aliquot was returned to the centrifuge tube after measurement. After several
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measurements, 50 mmol of glutathione was added to the centrifuge tube and aliquots were
taken and their absorbances measured via UV-Vis spectroscopy.

Cell toxicity experiment
To determine cell toxicity of the polysoaps, a standard MTT cell assay was
conducted.25 Cervical adenocarcinoma (KB) cells (10,000 cells per mL, 100 μL) were
seeded in a 96-well plate (Corning Inc.) in a phosphate-buffered saline solution. Cells were
treated with 10 μL of a polymer stock solution (50, 25, 10, and 5 μg/mL). Cell proliferation
was determined via a standard MTT assay (Vybrant MTT Cell Proliferation Assay Kit;
Invitrogen). Cells were incubated for 24 hrs prior to adding 10 µL of the 12 mM MTT
reagent to each well. The cells were incubated for an additional 4 hrs, followed by adding
100 µL of a sodium dodecyl sulfate (10%)/hydrochloric acid (0.01 M) solution to each
well. The absorbance was then determined utilizing a Biotek Synergy2 MultiMode
Microplate Reader. All studies were performed in triplicate.

Characterization of polysoaps
Dynamic light scattering (DLS) data were collected using incident light at 633 nm
from a Research Electro Optics HeNe laser operating at 40 mW. The time-dependent
scattering intensities were measured with a Brookhaven Instruments BI-200SM
goniometer at 60, 75, 90, 105, and 120o with an avalanche photodiode detector and
TurboCorr correlator. The decay rate was collected from a quadratic fit of the
autocorrelation function. The data was processed using Mathcad with the following steps:
decay rate was plotted versus q2 to generate a straight line. The slope of the line is the
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diffusion coefficient. The diffusion coefficient was then used in the Stokes-Einstein
equation to calculate the hydrodynamic radius of the particles. The radius was multiplied
by two to produce the hydrodynamic diameter, which was reported for the DLS
experimental data. An example of the DLS data processing can be found in the appendix
(Figure A9).
Gel permeation chromatography (GPC) was performed using an assembled
instrument with a Hewett Packard Series 1100 HPLC pump in-line with a Viscotek T60A
Dual Detector and a Viscotek VE3580 IR detector. The GPC system was equipped with
Tosoh TSKgel Super AW guard column, Super AW3000, and Super AW4000 columns in
series. The eluent used for the polysoap was 0.2 M lithium perchlorate in methanol. The
SEC software used to process the data was OmniSEC version 4.7.
All UV-Vis spectroscopy measurements were performed with an Agilent
Technologies Carey Series UV-Vis-NIR Spectrophotometer run by Carey WinUV
software. All steady-state fluorescence measurements were performed with a PTI-Horiba
QuantaMaster 400 spectrofluorimeter equipped with a 75 W Xe arc lamp.
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Chapter IV
Results and Discussion

Structural design of biocompatible polysoaps
To study the solution properties and feasibility for drug delivery of responsive
polysoaps, we prepared two statistical copolymers via the RAFT copolymerization of
HPMA and DPDMA (Scheme 4). The DPDMA monomer was designed to form the
hydrophobic domain of the micelles. Additionally, as desired for our polysoap design, the
hydrophobic dodecyl disulfide functionality has the ability to be reductively cleaved to a
thiol, providing for responsive hydrophobic domain dissociation and drug release. The
HPMA monomer was chosen to form the water-soluble corona of the micelles and is
biocompatible and non-immunogenic. Monomer content for this study was based on
previous work conducted in our group,26 which indicated the necessity of sufficient
hydrophobic content to form core domains in the micelles. However, since the coronas in
our polymeric micelles are neutral, water solubility can be compromised with too high a
hydrophobic content. To ensure water solubility and micelle formation, mole percentages
of 5% and 10% DPDMA were targeted. The resulting copolymers had weight average
molecular weights of 37.9 and 33.7 kDa and Mw/Mn values of 1.08 and 1.09, respectively
(Table 1). Figure 1 shows the SEC traces of the polysoap samples. From these traces we
observed that the polymerizations resulted in narrow and unimodal molecular weight
distributions, characteristics that are necessary for well-defined micelles for drug delivery
applications.
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Scheme 4. Synthesis of biocompatible, responsive polysoap poly(DPDMA-stat-HPMA).
Table 1. Structural details of poly(DPDMA-stat-HPMA) series.*
Sample

Conversiona

DPDMA Contenta

Mw/kDab

Mw/Mn

5% DPDMA

33%

7.77%

37.9

1.08

10% DPDMA

33%

15.4%

33.8

1.06

a

Determined by 1H NMR.
Determined by SEC-MALS.
*All polymerizations were conducted at 30 oC in dimethylformamide until the desired
monomer conversion was achieved.
b

70
60

5% DPDMA
10% DPDMA

RI Intensity

50
40
30
20
10
0
3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

Retention Volume (mL)

Figure 1. Size exclusion chromatography (SEC) traces of polysoaps. Eluent: 0.05 M
LiClO4 in MeOH. Flow rate: 0.3 mL/min.
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Polysoap properties in water
It was expected that the polysoap micelles would arrange into well-defined particles
of specific sizes. Dynamic light scattering (DLS) is a well-understood technique that allows
for the determination of the hydrodynamic diameters of the respective polysoap micelles
in water as a function of polymer concentration (Figure 2a). The size of the 5% DPDMA
sample indicates that a unimeric micelle is possibly formed, with consistent values of
approximately 11 nm across the concentration range measured. The 10% DPDMA sample,
however, exhibits larger relative sizes of around 60 nm, suggesting that multimeric
micelles or aggregates are formed. This can be attributed to increased hydrophobicity, and,
without a charged corona to stabilize the micelle electrosterically, inter-core mixing may
be prominent at higher hydrophobic contents. Notably, the hydrodynamic diameters of both
samples do not increase with concentration, which reveals that the uni- and multi-meric
micelles of the 5% and 10% DPDMA polysoaps, respectively, are stable at the
experimentally measured concentrations and hydrophobic contents.

Figure 2. a) Hydrodynamic diameter dependence on polysoap concentration in water
as measured by dynamic light scattering; b) Scattering intensity dependence on
polysoap concentration in water as measured by static light scattering at 90o.
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In Figure 2b, the scattering intensity of the polysoap solutions as a function of
polymer concentration is shown. The sample with 10% molar hydrophobe content has
consistently higher intensities and a greater slope compared to the 5% polysoap sample.
Since scattering intensity scales with the size of a point scatterer, this is in agreement with
larger particle sizes being observed in the DLS experiments for the 10% samples. The
scattering intensity is also shown to increase relatively linearly with concentration,
indicating a consistent aggregation number and size of the copolymers in solution.
Once the formation of particles was confirmed via DLS, the nature of the
hydrophobic core domains was probed. This was accomplished through fluorescence
spectroscopy measurements of pyrene in solution with respect to increasing concentration
of polysoap. The intensity of the vibronic peaks in the fluorescent spectrum of pyrene
changes with the hydrophobicity of the microenvironment of the pyrene. 27,28 Specifically,
the ratio of the intensity of the third to the first vibronic peak of pyrene increases as the
environment of the pyrene becomes more hydrophobic. As is shown in Figure 3, pyrene
becomes associated with the hydrophobic core domain of the polysoap micelles. As the
polysoap concentration increases, so does the I3/I1 ratio, indicating a more defined
hydrophobic microdomain in the core of the micelles. Furthermore, it is observed that 10%
DPDMA with its higher hydrophobic content elevates the ratio of the peak intensities more
than does 5% DPDMA. An interesting observation is the increase in ratio with polymer
concentration. This indicates that the domains are becoming more hydrophobic as polymer
concentration increases. This is unexpected for unimeric micelles but is observed in both
the 10% and 5% DPDMA systems, suggesting multimeric aggregates for these systems.
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Regardless, micelles form even at very low concentrations of 0.1 mg/mL, indicated by
particle formation and some degree of hydrophobic core definition.
Next, the capacity for hydrocarbon uptake was tested and measured using UV-Vis
spectroscopy. Shown in Figure 4, the absorbance of pyrene increased with increasing
polysoap concentration in deionized water. This demonstrates the ability of the polysoaps
to take up hydrocarbon, as increased amounts of polysoap are seen to correlate linearly
with increased amounts of pyrene dispersed in solution. In addition, of the two samples,
the 10% DPDMA exhibited greater uptake efficiency, indicative of larger or more welldefined hydrophobic core domains with increased hydrophobe content and consistent with
the elevated I3/I1 ratios from the fluorescence experiments. The 5% DPDMA still
sequesters pyrene but to a lesser extent. Nonetheless, both samples have the capability to
disperse pyrene even at lower concentrations.

1.2
5% DPDMA
10% DPDMA

I3/I1

1.0

0.8

0.6

0.4
0.1

1

10

Concentration (mg/mL)

Figure 3. Probing the hydrophobic domain of the polysoaps at varying concentrations
using pyrene I3/I1 ratios.
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10% DPDMA
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0.5
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Figure 4. Pyrene sequestration as measured by UV-absorbance at 338 nm as a
function of polysoap concentration.

Hydrocarbon retention and release experiments
Thus far, it has been demonstrated that polysoaps in aqueous solution form micelles
with core domains capable of hydrocarbon uptake. Next, we studied the retention and
triggered release of hydrocarbon, both essential for effective drug delivery. First, the
polysoaps were studied relative to hydrocarbon retention and release in the presence and
absence of glutathione as the reducing agent. 9-Anthracenemethanol was used as a model
hydrophobe capable of partitioning into water to a small extent. This experiment relied on
dialysis of the analyte through a membrane that retained the polymer. A signal in the
dialysate indicates hydrocarbon release. As shown in Figure 5, the polysoap was sufficient
at retaining the hydrocarbon in water. Additionally, glutathione was observed to be
ineffective as a reducing agent in the time frame of the experiment, as its addition to
solution did not significantly increase the relative absorbance of the hydrophobe in the
dialysate. Had the desired release mechanism occurred, the glutathione would have reduced
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the disulfide bond of the DPDMA units, changing those units to hydrophilic, and thus
disrupting the hydrophobic core domain. This would have triggered the release of the
sequestered hydrophobe and would have resulted in an increase in relative absorbance of
the dialysate. Instead, the rate of increase of the relative absorbance seems unaffected by
the addition of glutathione, suggesting insufficient domain formation or the absence of the
desired disulfide bond cleavage. The desired release mechanism is obviously not operative,
and the reason must be determined before charting a new strategy for the application of
this technology to drug delivery.

Figure 5. Absorbance of 9-anthracenemethanol in dialysate via dialysis against water.
The dialysis bag contained 1 mL of polymer solution (5 mg/mL).

Retention of the hydrocarbon in the presence of a nonpolar solvent was also
examined. For proper circulation of a loaded drug delivery vehicle until it has reached its
target, the vehicle must not prematurely release or leak its drug payload. As partitioning of
the payload to other tissue may occur inside the body, it is important to determine if this
23

will occur. As is shown in Figure 6, using ethyl acetate, an organic solvent, premature
partitioning of the 9-anthracenemethanol into the organic layer occurred. This is undesired,
as the loaded drug delivery vehicle needs to be able to retain its payload in similarly
hydrophobic areas in the body, such as in fat tissue. Furthermore, the addition of
glutathione had no significant effect on the release of hydrophobe, likely due to significant
release of hydrophobe prior to glutathione addition. This illustrates that the polysoap
system of this study must be altered to increase hydrophobic core domain stability and
definition to avoid premature partitioning of the hydrophobe from the delivery vehicle and
increase hydrophobe retention.

Figure 6. Absorbance of 9-anthracenemethanol in ethyl acetate (5 mL) via extraction
from 5 mL of polymer solution (5 mg/mL).
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Cell toxicity
Finally, the cell toxicity of the polysoaps was tested to determine biocompatibility
with KB cells. As is seen in Figure 7, relative to the control, the toxicity of all the tested
concentrations of polysoap was negligible for both polymer samples. Differences in
toxicity in this test are within experimental error, which was large for the tests performed.
Further experiments with larger sample sizes will be required for statistical confirmation
of the overall toxicity; however, initial experiments conclude that these polysoaps may
safely be used in vitro.

1.4
1.2

Cell Viability

1.0
Control
5
10
25
50

0.8
0.6
0.4
0.2
0.0
5% DPDMA

10% DPDMA

Figure 7. Cell viability determined via MTT cell assay at different concentrations of
polymer sample, in μg/mL.
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Chapter V
Conclusions

A series of biocompatible, responsive polysoaps was prepared via RAFT
copolymerization. As determined by DLS, UV-Vis, and fluorescence spectroscopy, the
polysoaps assemble into micelles that possess domains capable of sequestering
hydrocarbons in water. Hydrocarbon retention experiments during dialysis against water
suggest that the micelle core domains retain 9-anthracenemethanol in water, indicated by
relatively small amount of hydrophobe in the dialysate. Furthermore, addition of
glutathione to the dialysis solution did not result in the expected release of the hydrocarbon
within the time frame of the experiment. Hydrocarbon partitioning experiments in the
presence of ethyl acetate indicate that the polysoaps do not retain the hydrophobe, with
nearly complete partitioning of 9-anthracenemethanol into the organic layer. Additionally,
the partitioning did not require glutathione cleavage of the disulfide linkage. The polysoaps
are relatively non-toxic, as determined by a minimal decrease in cell viability as compared
to the control. Though the polysoap design is promising for drug delivery based on efficient
hydrocarbon uptake and biocompatibility, further studies and alterations to the structural
design will be necessary to optimize hydrocarbon retention and triggered release for such
applications.
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Appendix

Synthesis of CEP

Scheme A1. Synthesis of RAFT chain transfer agent, CEP.

Figure A1. 1H-NMR of CEP.
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Synthesis of HPMA

Scheme A2. Synthesis of HPMA.

Figure A2. 1H-NMR of HPMA.
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Synthesis of DPDMA

Scheme A3. Synthesis of DPDMA.

Figure A3. 1H-NMR of sodium methanethiosulfonate.
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Figure A4. 1H-NMR of aminopropyl sodium methanethiosulfonate.
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Figure A5. 1H-NMR of aminopropyl dodecyl disulfide.

Figure A6. 1H-NMR of DPDMA.
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1H-NMRs

of polysoaps

Figure A7. 1H-NMR of 5% DPDMA polysoap.
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Figure A8. 1H-NMR of 10% DPDMA polysoap.
Dynamic light scattering data processing

Figure A9. An example of DLS data processing using Mathcad of the 5% DPDMA
sample at 5 mg/mL.
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Dynamic and static light scattering data
Table A1. Calculated DLS and raw SLS data.
Concentration (mg/mL)

Dh (nm)

I (kcps)
std (of I)
5% DPDMA
5.0
12.0
83.3
0.94
3.0
11.6
56.4
1.12
1.9
12.6
37.1
0.80
1.0
11.3
22.1
1.33
0.5
14.9
12.0
0.43
0.1
11.3
4.33
0.18
10% DPDMA
5.0
56.1
919
14.6
3.0
57.5
693
11.3
2.0
59.4
539
8.44
1.0
58.4
348
6.30
0.5
59.9
198
3.85
0.1
60.6
34.8
0.63
*DLS data determined from autocorrelation functions at 60, 75, 90, 105, and 120o.
*SLS data determined from raw scattering intensities at 90o.
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